Mustang Bio in-licenses gene therapy cell line from CSL Behring

Mustang Bio (MBIO +2.8%) inks an agreement with CSL Behring for the rights to its Cytegrity stable producer cell line developed and used by St. Jude Children’s Research Hospital. It will use it to produce the viral vector for gene therapy MB-107 for the treatment of X-linked severe combined immunodeficiency.

Mustang in-licensed MB-107 from St. Jude a year ago.

Financial terms are not disclosed.

https://seekingalpha.com/news/3494883-mustang-bio-licenses-gene-therapy-cell-line-csl-behring-shares-3-percent